ライフサイエンスコーパス: remifentanil

1 at baseline, as well as their changes under remifentanil.

2 y during the withdrawal period of the opioid remifentanil.

3 ion (supramarginal gyrus) were unaffected by remifentanil.

4 short breath hold is modulated by the opioid remifentanil.

5 o-breathe score, was profoundly reduced with remifentanil.

6 edetomidine, with or without the addition of remifentanil.

7 on newly proposed clinical applications for remifentanil.

8 veness of the measure to the analgesic agent remifentanil.

9 acebo, and two effect site concentrations of remifentanil (1 and 2 microg/ml), an mu-opioid agonist.

10 ificantly attenuated in mice pretreated with remifentanil (159 vs 805 pg/ml of IL-6 after saline pret

11 drug (the short-acting mu receptor agonist, remifentanil) acquires incentive motivational properties

12 Remifentanil and expectancy both reduced pain, but drug

13 Remifentanil appears particularly attractive for this pu

14 d reports of novel clinical applications for remifentanil are frequently appearing in the anesthesia

15 Second, recent data relating to the use of remifentanil are reviewed.

16 Preconditioning with remifentanil attenuates intestinal IRI and the subsequen

17 biophysical data to support (+)-naloxone and remifentanil binding to TLR4/MD2.

18 ia with sevoflurane-remifentanil or propofol-remifentanil can keep patients immobile without producin

19 intravenous injections of the opioid agonist remifentanil functioned as positive reinforcers in both

20 In fact, the mucosa in the remifentanil group was as healthy as that of sham-operat

21 Remifentanil has a place in obstetric anaesthesia and an

22 ntravenous self-administration of the opioid remifentanil in a drug-concentration-dependent manner.

23 ave reliable anticonvulsant effects, whereas remifentanil in larger doses and sevoflurane appear to s

24 mmarizes the knowledge to date of the use of remifentanil in obstetric anaesthesia and analgesia.

25 Localized remifentanil-induced decreases in breath hold-related ac

26 We also observed remifentanil-induced decreases in the BOLD response to b

27 Remifentanil infusion in acute pain decreases the activa

28 Remifentanil is effective at obtunding responses to airw

29 Remifentanil is still in its infancy in terms of postmar

30 Pretreatment with remifentanil markedly reduced intestinal IRI (P < 0.001)

31 Propofol, dexmedetomidine, ketamine and remifentanil may be used in combination with anesthetic

32 Additional opioids recently studied include remifentanil, methadone, tramadol, and codeine.

33 receive tail vein injections of 1 mug/kg of remifentanil or normal saline and underwent either ische

34 Moderate anesthesia with sevoflurane-remifentanil or propofol-remifentanil can keep patients

35 as significantly lower than that of cocaine, remifentanil, or buprenorphine in monkeys responding und

36 dation was prevented by preconditioning with remifentanil (P < 0.05).

37 on selected advances in our understanding of remifentanil pharmacokinetics and pharmacodynamics and o

38 ference was detected between the saline- and remifentanil-pretreatments in any of the parameters inve

39 sthesia, such as combination of propofol and remifentanil, provides best preservation of autoregulati

40 handled rats following repeated exposure to remifentanil reveals a suppression of pro-inflammatory c

41 ociated with higher analgesic sensitivity to remifentanil (SaO(2), P = 0.0440; IGFBP-1, P = 0.0013).

42 discovered that pDNA-IL-10 treatment reduces remifentanil self-administration in a drug-concentration

43 although an attenuation of either cocaine or remifentanil self-administration was obtained at the hig

44 (+)-Naloxone also reduced opioid (remifentanil) self-administration (rats), another common

45 g effects of cocaine and the opioid agonist, remifentanil, tested under intravenous self-administrati

46 We administered the opioid agonist remifentanil to human subjects during experimental therm

47 ture response was substantially reduced when remifentanil was administered.

48 resonance imaging and the mu-opioid agonist remifentanil, we found that the magnitude of behavioral

49 We hypothesized that remifentanil would differentially depress brain areas th